Prenatal diagnosis after assisted reproductive technology

Pregnancy After Assisted Reproductive Technology

Volumn , Issue , 2006, Pages 149-167

  Ben Ami, Ido ^a   Maymon, Ron ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84888238533     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511902604.013     Document Type: Chapter

References (106)

1. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down’s syndrome. J Med Screen 1997; 4: 181–246.
2. Cuckle H. Antenatal screening for Down’s syndrome. Lancet 1998; 352: 1144–1145.
3. Van Lith JM, Pratt JJ, Beekhuis JR, Mantingh A. Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down’s syndrome. Prenat Diagn 1992; 12: 801–806.
4. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down’s syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999; 341: 461–467.
5. Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for Down’s syndrome with the quadruple test. Lancet 2003; 361: 835–836.
6. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343–346.
7. Pandya PP, Snijders RJ, Johnson SP, De Lourdes Brizot M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 1995; 102: 957–962.
8. Szabo J, Gellen J. Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester. Lancet 1990; 336: 1133.
9. Reynders CS, Pauker S, Benacerraf BR. First trimester isolated fetal nuchal lucency: significance and outcome. J Ultrasound Med 1997; 16: 101–105.
10. Fukada Y, Yasumizu T, Takizawa M, Amemiya A, Hoshi K. The prognosis of fetuses with transient nuchal translucency in the first and early second trimester. Acta Obstet Gynecol Scand 1997; 76: 913–916.
11. Haddow JE, Palomaki GE, Knight GJ, et al. Screening of maternal serum for fetal Down’s syndrome in the first trimester. N Engl J Med 1998; 338: 955–961.
12. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancyassociated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231–237.
13. De Biasio P, Siccardi M, Volpe G, et al. First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy – the combined test. Prenat Diagn 1999; 19: 360–363.
14. de Graaf IM, Pajkrt E, Bilardo CM, et al. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. Prenat Diagn 1999;19: 458–462.
15. Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides K. Absence of nasal bone in fetuses with trisomy 21 at 10–14 weeks of gestation: an observational study. Lancet 2001; 358: 1665–1667.
16. Cicero S, Rembouskos G, Vandecruys H, Hogg M, Nicolaides KH. Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 10–14-week scan. Ultrasound Obstet Gynecol 2004; 23: 218–223.
17. Rosen T, D’Alton ME, Platt LD, et al. First-trimester ultrasound assessment of the nasal bone to screen for aneuploidy. Obstet Gynecol 2007; 110: 399–404.
18. Borrell A. Promises and pitfalls of first trimester sonographic markers in the detection of fetal aneuploidy. Prenat Diagn 2009; 29: 62–68.
19. Maymon R, Jauniaux E. Down’s syndrome screening in pregnancies after assisted reproductive techniques: an update. Reprod Biomed Online 2002; 4: 285–293.
20. Geipel A, Gembruch U, Ludwig M, et al. Genetic sonography as the preferred option of prenatal diagnosis in patients with pregnancies following intracytoplasmic sperm injection. Hum Reprod 1999;14: 2629–2634.
21. Pinborg A, Loft A, Rasmussen S, et al. Neonatal outcome in a Danish national cohort of 3438 IVF/ICSI and 10,362 non-IVF/ICSI twins born between 1995 and 2000. Hum Reprod 2004; 19: 435–441.
22. Gjerris AC, Loft A, Pinborg A, ChristiansenM, TaborA. Prenatal testing among women pregnant after assisted reproductive techniques in Denmark 1995–2000: a national cohort study. Hum Reprod 2008; 23: 1545–1552.
23. Aboulghar H, Aboulghar M, Mansour R, et al. A prospective controlled study of karyotyping for 430 consecutive babies conceived through intracytoplasmic sperm injection. Fertil Steril 2001; 76: 249–253.
24. Bonduelle M, Van Assche E, Joris H, et al. Prenatal testing in ICSI pregnancies: incidence of chromosomal Hum Reprod 17 2002; 17: 2600–2614.
25. Jozwiak EA, Ulug U, Mesut A, Erden HF, Bahçeci M. Prenatal karyotypes of fetuses conceived by tracytoplasmic sperm injection. Fertil Steril 2004; 82:628–633.
26. serum screening in assisted reproduction versus naturally conceived singleton pregnancies. Prenat Diagn 1999; 19: 1007–1011.
27. Barkai G, Goldman B, Ries L, et al. Down’s syndrome screening marker levels following assisted reproduction. Prenat Diagn 1996; 16: 1111–1114.
28. Heinonen S, Ryynänen M, Kirkinen P, Hippeläinen M, Saarikoski S. Effect of in vitro fertilization on human chorionic gonadotropin serum concentrations and Down’s syndrome screening. Fertil Steril 1996; 66:398–403.
29. Ribbert LS, Kornman LH, De Wolf BT, et al. Maternal serum screening for fetal Down syndrome in IVF pregnancies. Prenat Diagn 1996; 16: 35–38.
30. Frishman GN, Canick JA, Hogan JW, et al. Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies. Obstet Gynecol 1997;90: 98–101.
31. Wald NJ, White N, Morris JK, Huttly WJ, Canick JA. Serum markers for Down’s syndrome in women who have had in vitro fertilisation: implications for antenatal screening. Br J Obstet Gynaecol 1999; 106:1304–1306.
32. Maymon R, Shulman A. Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies. HumReprod 2001; 16: 691–695.
33. Bar-Hava I, Yitzhak M, Krissi H, et al. Triple-test screening in in vitro fertilization pregnancies. J Assist Reprod Genet 2001; 18: 226–229.
34. Maymon R, Shulman A. Serial first- and secondtrimester Down’s syndrome screening tests among IVF-versus naturally-conceived singletons. Hum Reprod 2002; 17: 1081–1085.
35. Raty R, Virtanen A, Koskinen P, et al. Serum free beta- HCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal midtrimester serum screening for Down’s syndrome. Hum Reprod 2002; 17: 481–484.
36. Muller F, Dreux S, Lemeur A, et al. Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome. Prenat Diagn 2003; 23: 1073–1076.
37. Rice JD, McIntosh SF, Halstead AC. Second-trimester maternal serum screening for Down syndrome in in vitro fertilization pregnancies. Prenat Diagn 2005;25: 234–238.
38. Perheentupa A, Ruokonen A, Tuomivaara L, Ryynänen M, Martikainen H. Maternal serum beta-HCG and alpha-fetoprotein concentrations in singleton pregnancies following assisted reproduction. Hum Reprod 2002; 17: 794–797.
39. Weisz B, Rodeck C.H. An update on antenatal screening for Down’s syndrome and specific implications for ssisted reproduction pregnancies. Hum Reprod Update 2006; 12: 513–518.
40. Marrs R, Kletzky OA, Howard WF, Mishell DR Jr. Disappearance of human chorionic gonadotropin and resumption of ovulation following abortion. Am J Obstet Gynecol 1979; 135: 731–736.
41. Lam YH, Yeung WS, Tang MH, et al. Maternal serum alpha-fetoprotein and human chorionic gonadotrophin in pregnancies conceived after intracytoplasmic sperm injection and conventional invitro fertilization. Hum Reprod 1999; 14: 2120–2123.
42. Shulman A, Maymon R. Mid-gestation Down syndrome screening test and pregnancy outcome among nstimulated assisted-conception pregnancies. Prenat Diagn 2003; 23: 625–628.
43. Hsu TY, Ou CY, Hsu JJ, et al. Maternal serum screening for Down syndrome in pregnancies conceived by intra-uterine insemination. Prenat Diagn 1999; 19: 1012–1014.
44. Maymon R, Cuckle H, Herman A. Maternal serum inhibin levels in twin and singleton pregnancies conceived by assisted reproduction. Hum Reprod 2006; 21: 1305–1308.
45. Jackson RA, Gibson KA, Wu YW, Croughan MS. Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. Obstet Gynecol 2004; 103:551–563.
46. Kalra SK, Molinaro TA. The association of in vitro fertilization and perinatal morbidity. Semin Reprod Med 2008; 26: 423–435.
47. Ogle R, Jauniaux E, Pahal GS, et al. Serum screening for Down syndrome and adverse pregnancy outcomes: a case-controlled study. Prenat Diagn 2000; 20: 96–99.
48. Hui W, Lam YH, Tang MH, et al. Maternal serum pregnancy-associated plasma protein-A and free betahuman chorionic gonadotrophin in pregnancies conceived with fresh and frozen-thawed embryos from in vitro fertilization and intracytoplasmic sperm injection. Prenat Diagn 2005; 25: 390–393.
49. Engels MA, Kooij M, Schats R, et al. First-trimester serum marker distribution in singleton pregnancies conceived with assisted reproduction. Prenat Diagn 2010; 30: 372–377.
50. Wojdemann KR, Larsen SO, Shalmi A, et al. First trimester screening for Down syndrome and assisted reproduction: no basis for concern. Prenat Diagn 2001; 21: 563–565.
51. Bellver J, Lara C, Soares SR, et al. First trimester biochemical screening for Down’s syndrome in singleton pregnancies conceived by assisted reproduction. Hum Reprod 2005; 20: 2623–2627.
52. Lambert-Messerlian G Dugoff L, Vidaver J, et al. Firstand second-trimester Down syndrome screening markers in pregnancies achieved through assisted reproductive technologies (ART): a FASTER trialstudy. Prenat Diagn 2006; 26: 672–678.
53. Ghisoni L, Ferrazzi E, Castagna C, et al. Prenatal diagnosis after ART success: the role of early combined screening tests in counselling pregnant patients.Placenta 2003; 24: S99–S103.
54. Orlandi F, Rossi C, Allegra A, et al. First trimester screening with free beta-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenat Diagn 2002; 22: 718–721.
55. Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000; 107: 1265–1270.
56. Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod 2001; 16: 1501–1504.
57. Maymon R, Shulman A. Integrated first- and secondtrimester Down syndrome screening test among unaffected IVF pregnancies. Prenat Diagn 2004; 24:125–129.
58. Gjerris AC, Loft A, Pinborg A, Christiansen M, Tabor A. First-trimester screening markers are altered in pregnancies conceived after IVF/ICSI. Ultrasound Obstet Gynecol 2009; 33: 8–17.
59. Cicero S, Avgidou K, Rembouskos G, Kagan KO, Nicolaides KH. Nasal bone in first-trimester screening for trisomy 21. Am J Obstet Gynecol 2006; 195:109–114.
60. Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with fetal nuchal translucency thickness. Prenat Diagn 2000; 20: 91–95.
61. Cuckle H. Down’s syndrome screening in twins. J Med Screen 1998; 5: 3–4.
62. Doyle PE, Beral V, Botting B, Wale CJ. Congenital malformations in twins in England and Wales. J Epidemiol Community Health 1991; 45: 43–48.
63. Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG 2003; 110: 276–280.
64. Wald N, Cuckle H, Wu TS, George L. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down’s syndrome. Br J Obstet Gynaecol 1991; 98: 905–908.
65. Raty R, Virtanen A, Koskinen P, et al. Maternal midtrimester serum AFP and free beta-hCG levels in in vitro fertilization twin pregnancies. Prenat Diagn 2000; 20: 221–223.
66. Maymon R, Neeman O, Shulman A, Rosen H, Herman A. Current concepts of Down syndrome screening tests in assisted reproduction twin pregnancies: another double trouble. Prenat Diagn 2005; 25: 746–750.
67. Sepulveda W. Chorionicity determination in twin pregnancies: double trouble. Ultrasound Obstet Gynecol 1997; 10: 79–81.
68. Shetty A, Smith A. The sonographic diagnosis of chorionicity. Prenat Diagn 2005; 25: 735–739.
69. Wenstrom KD, Syrop CH, Hammitt DG, Van Voorhis BJ. Increased risk of monochorionic twinning associated with assisted reproduction. Fertil Steril 1993;60: 510–514.
70. Spencer K. Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free beta-hCG or PAPP-A levels? Prenat Diagn 2001; 21: 715–717.
71. Gonce A, Borrell A, Fortuny A, et al. First-trimester screening for trisomy 21 in twin pregnancy: does the addition of biochemistry make an improvement? Prenat Diagn 2005; 25: 1156–1161.
72. Wojdemann KR, Larsen SO, Shalmi AC, et al. Nuchal translucency measurements are highly correlated in both mono- and dichorionic twin pairs. Prenat Diagn 2006; 26: 218–220.
73. Spencer K, Kagan KO, Nicolaides KH. Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers. Prenat Diagn 2008; 28: 49–52.
74. Maymon R, Dreazen E, Rozinsky S, et al.Comparison of nuchal translucency measurement and second-trimester triple serum screening in twin versus singleton pregnancies. Prenat Diagn 1999; 19:727–731.
75. Kidd SA, Lancaster PA, Anderson JC, et al. A cohort study of pregnancy outcome after amniocentesis in twin pregnancy. Paediatr Perinat Epidemiol 1997; 11:200–213.
76. Cuckle H, Maymon R. Down syndrome risk calculation for a twin fetus taking account of the nuchal translucency in the co-twin. Prenat Diagn 2010; 30:827–833.
77. Maymon R, Rosen H, Baruchin O, Herman A, Cuckle H. Model predicted Down syndrome detection rates for nuchal translucency screening in twin pregnancies. Prenat Diagn 2011; 31:426–429.
78. Wald NJ, Rish S, Hackshaw AK. Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. Prenat Diagn 2003; 23: 588–592.
79. Maymon R, Jauniaux E, Holmes A, et al. Nuchal translucency measurement and pregnancy outcome after assisted conception versus spontaneously conceived twins. Hum Reprod 2001; 16: 1999–2004.
80. Cleary-Goldman J, Rebarber A, Krantz D, Hallahan T, Saltzman D. First-trimester screening with nasal bone in twins. Am J Obstet Gynecol 2008; 199: 283.e1–e3.
81. Spencer K, Salonen R, Muller F. Down’s syndrome screening in multiple pregnancies using alphafetoprotein and free beta hCG. Prenat Diagn 1994; 14:537–542.
82. Berkowitz RL, Lynch L, Stone J, Alvarez M. The current status of multifetal pregnancy reduction. Am J Obstet Gynecol 1996; 174: 1265–1272.
83. Maymon R, Herman A, Shulman A, et al. First trimester embryo reduction: A medical solution to an iatrogenic problem. Hum Reprod 1995; 10: 668–673.
84. Grau P, Robinson L, Tabsh K, Crandall BF. Elevated maternal serum alpha-fetoprotein and amniotic fluid alpha-fetoprotein after multifetal pregnancy reduction.Obstet Gynecol 1990; 76: 1042–1045.
85. Lynch L, Berkowitz RL. Maternal serum alphafetoprotein and coagulation profiles after multifetal pregnancy reduction. Am J Obstet Gynecol 1993; 169:987–990.
86. Groutz A, Amit A, Yaron Y, et al. Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction. Prenat Diagn 1996; 16: 723–727.
87. Shulman L, Phillips O. Re: second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction. Prenat Diagn 1997; 17: 488–490.
88. Shulman L, Phillips O, Cervetti TA. Maternal serum analyte levels after first-trimester multifetal pregnancy reduction. Am J Obstet Gynecol 1996; 174: 1072–1074.
89. Rotmensch S, Celentano C, Shalev J, et al. Midtrimester maternal serum screening after multifetal pregnancy reduction in pregnancies conceived by in vitro fertilization. J Assist Reprod Genet 1999; 16: 8–12.
90. Chen HJ, Huang LW, Lin YH, et al. Midtrimester maternal serum inhibin A levels after multifetal pregnancy reduction. Prenat Diagn 2007; 27: 431–434.
91. Pandya PP, Hilbert F, Snijders RJ, Nicolaides KH. Nuchal translucency thickness and crown-rump length in twin pregnancies with chromosomally abnormal fetuses. J Ultrasound Med 1995. 14: 565–568.
92. Maymon R, Dreazen E, Tovbin Y, et al. The feasibility of nuchal translucency measurement in higher order multiple gestations achieved by assisted reproduction. Hum Reprod 1999; 14: 2102–2105.
93. Sebire NJ, Snijders RJ, Hughes K, Sepulveda W, Nicolaides KH. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10–14 weeks of gestation.Br J Obstet Gynaecol 1996; 103: 999–1003.
94. Sebire NJ, Souka A, Skentou H, Geerts L, Nicolaides KH. Early prediction of severe twin-to-twin transfusion syndrome. Hum Reprod 2000; 15: 2008 2010.
95. Berkowitz RL, Lynch L, Lapinski R, Bergh P. Firsttrimester transabdominal multifetal pregnancy reduction: a report of two hundred completed cases. Am J Obstet Gynecol 1993; 169: 17–21.
96. Evans MI, Berkowitz RL, Wapner RJ, et al.Improvement in outcomes of multifetal pregnancy reduction with increased experience. Am J Obstet Gynecol 2001; 184: 97–103.
97. Sepulveda W, Sebire NJ, Odibo A, Psarra A, Nicolaides KH. Prenatal determination of chorionicity in triplet pregnancy by ultrasonographic examination of the ipsilon zone. Obstet Gynecol 1996;88: 855–858.
98. Dickey R, Olar TT, Taylor SN, et al. Incidence and significance of unequal gestational sac diameter or embryo crown-rump length in twin pregnancy. Hum Reprod 1992; 7: 1170–1172.
99. Achiron R, Tadmor O, Mashiach S. Heart rate as a predictor of first-trimester spontaneous abortion after ultrasound-proven viability. Obstet Gynecol 1991; 78:330–334.
100. Lipitz S, Shulman A, Achiron R, Zalel Y, Seidman DS. A comparative study of multifetal pregnancy reduction from triplets to twins in the first versus early second trimesters after detailed fetal screening. Ultrasound Obstet Gynecol 2001; 18: 35–38.
101. Cuckle HS. Growing complexity in the choice of Down’s syndrome screening policy. Ultrasound Obstet Gynecol 2002; 19: 323–326.
102. Brambati B, Tului L, Baldi M, Guercilena S. Genetic analysis prior to selective fetal reduction in multiple pregnancy: technical aspects and clinical outcome.Hum Reprod 1995; 10: 818–825.
103. Eddleman KA, Stone JL, Lynch L, Berkowitz RL.Chorionic villus sampling before multifetal pregnancy reduction. Am J Obstet Gynecol 2000; 183: 1078–1081.
104. Monni G, et al. Importance of nuchal translucency measurement in multifetal pregnancy reduction. Ultrasound Obstet Gynecol, 1999.13(5): 377–8.
105. Maymon R, Herman A. Multifetal pregnancy reduction. Am J Obstet Gynecol 2001;185:772–774.
106. Selam B, Torok O, Lembet A, et al. Genetic amniocentesis after multifetal pregnancy reduction.Am J Obstet Gynecol 1999; 180: 226–230.